$Pistol Pete$, $Mick$ & Friends Stock Picks /news, DD and charts

[$Pistol Pete$]

$PMCB No other treatment for diabetes currently in trials or available can claim reversal of diabetes without the use of an external device (pump) or subcutaneous device. A few months ago I posted DD regarding the possible side effects of a subcutaneous device. Summarily, here they are:




************************************************************************

The The Cell-in-a-Box®/Melligen cell combo performs an identical function, without the use of a medical device:

http://viacyte.com/technology/device-engineering/

Possible side effects from the device insertion/retraction procedure include, and may not be limited to: pain, bruising or swelling, redness, infection, and/or scarring. There’s a chance the device may be harder to remove if it was placed too deep. There's also a chance of malfunction due to improper insertion depth.
************************************************************************
Additional side effects of medical devices inserted just beneath the skin, otherwise known as subcutaneous, also include: possible sensitivity to the device material (which may/may not cause an allergic reaction) and excessive bleeding. Basically, a medical device increases the complexity of any treatment - never a good thing.
************************************************************************
http://www.healthline.com/diabetesmine/progress-report-diabetes-research-involving-that-c-word#1
************************************************************************
More possible side effects from a subcutaneous device could include fixation problems (device movement), resulting in itching/dry skin. People who suffer from eczema could also experience complications with a subcutaneous device.

Another invaluable trait of the The Cell-in-a-Box®/Melligen cell combo, aside from being completely bioinert, is the ability to allow the Melligen cells to secrete insulin without the need for any external devices. These qualities are imperative to achieving an efficacious treatment capable of producing the desired results, while also completely avoiding any immune system response.
************************************************************************
Additional problems & complications associated with subcutaneous devices may include: skin abscess (requiring an incision and drainage of the area, and a culture of the fluid), lipohypertrophy and lipodystrophy (more info here on both conditions:http://www.healthline.com/health/diabetes/lipohypertrophy)

PharmaCyte's Cell-in-a-Box®/Melligen cell combo requires no device whatsoever to produce insulin. Furthermore, the insulin-producing Melligen cells are protected from the immune system, thereby avoiding an immune system response.
************************************************************************
The four main areas to inject insulin are: abdomen, thigh, hip/buttock and the back of arm - this is where lipohypertrophy and lipodystrophy could obtrude a device location. Insulin injected into the abdomen is absorbed (and therefore put to work) the most quickly. Using the same insulin injection site over and over is not a good idea. Type 1 diabetics are more prone to suffer from lipohypertrophy and lipodystrophy as a result of not rotating insulin injection sites, thereby making a subcutaneous device undesirable.

http://www.healthline.com/health/diabetes/lipohypertrophy

PharmaCyte's Cell-in-a-Box®/Melligen cell combo to treat diabetes eliminates the need for daily/weekly/monthly insulin injections. It also requires no subcutaneous device and elicits no immune response.
************************************************************************
They can all run but they cannot hide from the Cell-in-a-Box® live cell encapsulation technology. ViaCyte isn't the only one going to human trials for diabetes:
http://jdrf.org/westernpa/2014/06/05/exciting-smart-insulin-research-news-this-is-why-we-walk/

Imo, the Cell-in-a-Box®/Melligen cell combo is far superior to any other diabetes treatment in existence and at any stage of testing. T1 diabetics desperately want/need a diabetes treatment which requires nothing on their part in terms of monitoring/maintenance/treatment: no more daily shots, no more testing for blood sugar 3-5 times daily, no more waking up in the middle of the night with hypoglycemia (low blood sugar) and no more maintenance/replacement of insulin pumps. The Cell-in-a-Box®/Melligen cell combo requires no external devices, no insulin pumps and no subcutaneous devices to produce insulin.

Go PharmaCyte Biotech!!!